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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
This review will aim to evaluate the benefits and harms of altering dietary salt intake for people with CKD.
B A C K G R O U N D
Description of the condition
Chronic kidney disease (CKD) is a major public health problem
worldwide; data from Australia, the United States, Japan, and Eu-
rope indicate that CKD occurs in 6% to 13% of people in these
populations (Chadban 2003;Coresh 2007; ElNahas 2005;Hamer
2006). Evidence indicates that the prevalence ofCKDis rapidly in-
creasing, which is at least partially explained by dramatic increases
in rates of diabetes and hypertension, two of the most common
causes of CKD (Coresh 2007). CKD is a progressive condition.
Once patients reach end-stage kidney disease (ESKD), dialysis or
transplantation is required to survive. In people with ESKD, risk
of mortality is 40 times that of the general population (Collins
2003), and the annual cost of care is increased approximately 10-
fold compared with CKD management (Hunsicker 2004).
CKD is also an independent risk factor for cardiovascular disease;
people with CKD are 5 to 10 times more likely to die of cardio-
vascular disease than progress to ESKD (Go 2004). Because both
cardiovascular disease and progression to ESKD may be delayed,
or possibly prevented, effective strategies to reduce these outcomes
are needed to improve patient prognosis and reduce healthcare
costs attributable to this population.
Description of the intervention
Excessive salt (sodium) intake is related to many risk factors for
cardiovascular disease and CKD progression including increased
blood pressure, fluid retention, proteinuria, inflammation, oxida-
tive stress and endothelial dysfunction (Al-Solaiman 2009; Ritz
2009). Salt restriction has been shown to have a beneficial effect
against risk factors such as hypertension and proteinuria, over and
above that provided by antihypertensive medications (Vogt 2008).
Despite this, evidence suggests salt restriction is not adequately
emphasised for people with CKD (Thijssen 2008). One of the
reasons for this may be that there is no clear consensus on the
benefits of reducing salt intake in people with CKD. Evidence-
based practice guidelines show inconsistencies in the ideal target
for salt intake in people with CKD, with salt targets ranging from
less than 3.8 g of salt (65 mmol sodium) per day to 6.5 g (110
mmol sodium) per day (Ash 2006; USDA 2010).
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How the intervention might work
Studies in the general population have consistently demonstrated
the link between dietary salt and blood pressure, particularly in
those who are ‘salt sensitive’ (He 2004; Svetkey 1999). A re-
cent meta-analysis on reducing salt intake in people with dia-
betic kidney disease also showed considerable blood pressure re-
ductions; systolic/diastolic blood pressure was lowered by 7/3 mm
Hg (Suckling 2010).
New evidence suggests salt has adverse effects independent of
blood pressure. Todd 2010 found arterial stiffness measured by
pulse wave velocity was significantly decreased independently of
blood pressure changes in hypertensive patients on a low salt diet.
Increased pulse wave velocity is a predictor of all-cause and car-
diovascular mortality (Guerin 2001). Proteinuria, a risk factor for
both CKD progression and cardiovascular disease in people with
CKD, has also shown to be reduced by salt restriction independent
of blood pressure (Verhave 2004).
Why it is important to do this review
Salt intake shows great promise as a modifiable risk factor for the
reduction in cardiovascular risk and CKDprogression even in very
early stages of the disease. However, clear consensus of the benefits
of reducing salt in people with CKD, and the optimal target salt
intake for this population, has yet to be established. This review
will evaluate the benefits and harms of altering dietary salt intake
in people with CKD, to reduce uncertainty and facilitate best
practice for managing salt intake for people with CKD.
O B J E C T I V E S
This review will aim to evaluate the benefits and harms of altering
dietary salt intake for people with CKD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and quasi-RCTs (RCTs in
which allocation to treatment was obtained by alternation, use
of alternate medical records, date of birth or other predictable
methods) measuring the effect of a low versus high salt intake in
people with CKD will be included.
Types of participants
Inclusion criteria
• Participants with CKD (as defined by Kidney Disease
Outcomes Quality Initiative (K/DOQI) Clinical Practice
Guidelines) at all stages (NKF 2002)
• Aged 18 years or over.
Exclusion criteria
• Pregnant women
• Children (aged up to 18 years).
Types of interventions
• Studies that compare two or more differing sodium intakes.
• Study period of at least one week.
• Sodium intake estimated by 24 hour urinary sodium
excretion (24 h UNa) with a minimum difference in 24 h UNa
of 34 mmol (2 g salt/d) achieved between allocated
interventions. Reduction in 24 h UNa will be calculated as the
difference between the UNa at the end of each intervention for
cross-over studies, and the difference in change between groups
from baseline to the end of intervention for parallel studies.
• We will included studies where concomitant interventions
such as antihypertensive medication or other dietary
modifications were used during the study period, providing that
these interventions were constant throughout the low and high
salt interventions.
Types of outcome measures
Primary outcomes
1. Cardiovascular mortality
2. All-cause mortality.
Secondary outcomes
1. Cardiovascular disease (coronary artery disease, heart
failure, cerebrovascular disease and peripheral vascular disease)
2. Progression to ESKD requiring dialysis or transplantation
3. Change in blood pressure (clinic and ambulatory)
4. Change in arterial stiffness (pulse wave velocity and
augmentation index)
5. Change in renal function measures (creatinine clearance,
serum creatinine, proteinuria, glomerular filtration rate)
6. Change in markers of fluid overload (brain natriuretic
peptide, weight, bio-impedance analysis)
7. Change in markers of oxidative stress or inflammation (C-
reactive protein, adipokines)
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8. Adverse events: Hypotensive episodes, undesirable change
in blood lipids (low density lipoprotein, high-density
lipoprotein).
Search methods for identification of studies
Electronic searches
We will search the Cochrane Renal Group’s Specialised Register
through contact with the Trials’ Search Co-ordinator using search
terms relevant to this review. The Cochrane Renal Group’s Spe-
cialised Register contains studies identified from sources.
• Quarterly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
• Weekly searches of MEDLINE OVID SP
• Handsearching of renal-related journals and the
proceedings of major renal conferences
• Searching of the current year of EMBASE OVID SP
• Weekly current awareness alerts for selected renal journals
• Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts are available in the Specialised
Register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of nephrology textbooks, review articles and
relevant studies.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts will be screened independently by two authors, who
will discard studies that are not applicable; however, studies and
reviews that might include relevant data or information on studies
will be retained initially. Two authors will independently assess
retrieved abstracts and, if necessary the full text, of these studies
to determine which studies satisfy the inclusion criteria.
Data extraction and management
Data extraction will be carried out independently by two authors
using standard data extraction forms. Studies reported in non-
English language journals will be translated before assessment.
Where more than one publication of one study exists, reports will
be grouped together and the publication with the most complete
data will be used in the analyses. Where relevant outcomes are
only published in earlier versions these data will be used. Any
discrepancy between published versions will be highlighted.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (seeAppendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (cardiovascular mortality, all-cause
mortality, progression to ESKD, cardiovascular disease) results will
be expressed as risk ratios (RR) with 95% confidence intervals
(CI). Where continuous scales of measurement are used to assess
the effects of treatment (blood pressure, pulse wave velocity, aug-
mentation index, creatinine clearance, serum creatinine, protein-
uria, glomerular filtration rate, brain natriuretic peptide, weight,
bio-impedance analysis, C-reactive protein, adipokines) the mean
difference (MD) will be used, or the standardised mean difference
(SMD) if different scales have been used. Studies analysing change
scores will be included in meta-analysis along with studies includ-
ing the endpoint data only.
Where change from baseline values are absent, these will be cal-
culated by subtracting mean value at the end of the interven-
tion to baseline values (parallel studies) or subtracting the value
from the end of the higher sodium phase from the lower sodium
phase (cross-over studies). Standard deviations for change may be
imputed where appropriate using the methods outlined in the
Cochrane Handbook (Higgins 2011).
When investigating time-to-event data (i.e. survival), a summary
of the outcomes will be made using Kaplan-Meier analysis with
the intervention effect expressed as a hazard ratio (Higgins 2011)
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Unit of analysis issues
In cross-over studies, wewill determine theMD in outcomes as the
difference between the end of the low salt period and the end of the
high salt period. For parallel studies we will calculate the treatment
effect as the difference between the two treatment groups in the
change in outcomes from baseline.
Dealing with missing data
Any further information required from the original author will be
requested by written correspondence (e.g. emailing and/or writing
to corresponding author/s) and any relevant information obtained
in this manner will be included in the review. Evaluation of im-
portant numerical data such as screened, randomised patients as
well as intention-to-treat, as-treated and per-protocol population
will be carefully performed. Attrition rates, for example drop-outs,
losses to follow-up and withdrawals will be investigated. Issues of
missing data and imputation methods (for example, last-observa-
tion-carried-forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
Heterogeneity will be analysed using a Chi² test on N-1 degrees
of freedom, with an alpha of 0.05 used for statistical significance
and with the I² test (Higgins 2003). I² values of 25%, 50% and
75% correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixed-
effect model will also be used to ensure robustness of the model
chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be used to explore possible sources of het-
erogeneity (e.g. intervention duration, levels of sodium intake).
Heterogeneity among participants could be related to age, stage
of CKD, presence of comorbidities (e.g. hypertension and dia-
betes) and renal pathology (e.g. dialysed versus non-dialysed pa-
tients with CKD).
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size:
• repeating the analysis excluding unpublished studies
• repeating the analysis taking account of risk of bias, as
specified
• repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), country.
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. sodium chloride:kw
2. ((sodium or salt) near/5 (low or high or alter* or reduce* or reducing or reduction or restrict* or intake* or diet*
or increas* or decreas* or change* or changing)):ti,ab,kw
3. (#1 OR #2)
4. “renal replacement therapy”:ti,ab,kw
5. (h*emodialysis or h*emofiltration or h*emodiafiltration):ti,ab,kw
6. dialysis:ti,ab,kw
7. (CAPD or CCPD or APD):ti,ab,kw
8. (“kidney disease” or “kidney diseases” or “renal disease” or “renal diseases”):ti,ab,kw
9. (chronic next kidney or chronic next renal):ti,ab,kw
10. ((kidney next failure) or (renal next failure)):ti,ab,kw
11. (“end-stage kidney” or “end-stage renal” or “endstage kidney” or “endstage renal”):ti,ab,kw
12. (ESRF or ESKF or ESRD or ESKD):ti,ab,kw
13. (CKF or CKD or CRF or CRD):ti,ab,kw
14. (predialysis or “pre-dialysis”):ti,ab,kw
15. (nephropath* or nephrit* or glomerulo*):ti,ab,kw
16. (glomerular next disease*):ti,ab,kw
17. (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16)
18. (#3 AND #17)
MEDLINE 1. exp Sodium Chloride/
2. Diet, Sodium Restricted/
3. ((sodium or salt) adj5 (low or high or alter* or reduce* or reduction or restrict* or intake* or diet* or increas* or
decreas* or change* or changing)).tw.
4. or/1-3
5. Renal Replacement Therapy/
6. exp Renal Dialysis/
7. (hemodialysis or haemodialysis).tw.
8. (hemofiltration or haemofiltration).tw.
9. (hemodiafiltration or haemodiafiltration).tw.
10. dialysis.tw.
11. (CAPD or CCPD or APD).tw.
12. exp Kidney Diseases/
13. (kidney disease* or renal disease*).tw.
14. (nephropath* or nephrit* or glomerulo* or glomerular disease*).tw.
15. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
16. (ESRF or ESKF or ESRD or ESKD).tw.
17. (chronic kidney or chronic renal).tw.
18. (CKF or CKD or CRF or CRD).tw.
19. (predialysis or pre-dialysis).tw.
20. or/5-19
21. and/4,20
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(Continued)
EMBASE 1. Sodium Chloride/
2. Salt Intake/
3. Sodium Restriction/
4. Sodium Intake/
5. ((sodium or salt) adj5 (low or high or alter* or reduce* or reduction or restrict* or intake* or diet* or increas* or
decreas* or change* or changing)).tw.
6. or/1-5
7. exp Renal Replacement Therapy/
8. (hemodialysis or haemodialysis).tw.
9. (hemofiltration or haemofiltration).tw.
10. (hemodiafiltration or haemodiafiltration).tw.
11. dialysis.tw.
12. (CAPD or CCPD or APD).tw.
13. exp Kidney Disease/
14. (kidney disease* or renal disease*).tw.
15. (nephrop* or nephrit* or glomerulo* or glomerular disease*).tw.
16. (chronic kidney or chronic renal).tw.
17. (CKF or CKD or CRF or CRD).tw.
18. (end-stage renal or end-stage kidney or endstage renal or endstage kidney).tw.
19. (ESRF or ESKF or ESRD or ESKD).tw.
20. (predialysis or pre-dialysis).tw.
21. or/7-20
22. and/6,21
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
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(Continued)
quate concealment of allocations prior to assignment group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
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(Continued)
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
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(Continued)
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
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